Visit http://indiaer.blogspot.com/ for complete details Dishman Pharma (CMP: `180, TP: `245, Outperform)
• On account of slow recovery in its Indian operations as well as in its Swiss arm Carbogen Amcis, Dishman Pharma is likely to report a flat top-line growth in 2QFY11.
• EBITDA too is likely to show a nominal growth of ~0.6% YoY due to flat margin.
• Net profit will likely show a marginal 0.7% decline
No comments:
Post a Comment